PuSH - Publication Server of Helmholtz Zentrum München

79 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
Lay all publications on this page into basket
1.
Absmaier, M.* et al.: PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients. Int. J. Oncol. 52, 755-767 (2018)
2.
Dalke, C. et al.: Lifetime study in mice after acute low-dose ionizing radiation: A multifactorial study with special focus on cataract risk. Radiat. Environ. Biophys. 57, 99-113 (2018)
3.
Yang, F.* et al.: Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer. Biol. Chem. 398, 1151-1164 (2017)
4.
Falkenberg, N. et al.: Three-dimensional microtissues essentially contribute to preclinical validations of therapeutic targets in breast cancer. Cancer Med. 5, 703-710 (2016)
5.
Gross, E.* et al.: Validation of a BRCAness test to select for targeted therapies in triple-negative breast cancer. Oncol. Res. Treat. 39, 54 (2016)
6.
Gross, E.* et al.: Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: A validation study. BMC Cancer 16:811 (2016)
7.
Huber, M. et al.: Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer. Oncotarget 7, 44062-44075 (2016)
8.
Huber, M. et al.: uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R. BMC Cancer 16:615 (2016)
9.
Ly, A. et al.: High-mass-resolution MALDI mass spectrometry imaging of metabolites from formalin-fixed paraffin-embedded tissue. Nat. Protoc. 11, 1428-1443 (2016)
10.
Aubele, M.: Genetik für Ahnungslose : Eine Einstiegshilfe für Studierende. Stuttgart: Hirzel, 2015. 187 S.
11.
Aubele, M. et al.: uPA receptor and its interaction partners: Impact as potential therapeutic targets in triple-negative breast cancer. J. Clin. Oncol. 33:150 (2015)
12.
Buck, A. et al.: High-resolution MALDI-FT-ICR MS imaging for the analysis of metabolites from formalin-fixed paraffin-embedded clinical tissue samples. J. Pathol. 237, 123–132 (2015)
13.
Falkenberg, N. et al.: Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo. Mol. Oncol. 9, 282-294 (2015)
14.
Falkenberg, N. et al.: Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221. Oncotarget 6, 8103-8114 (2015)
15.
Huber, M. et al.: The impact of the uPAR system and its interaction partners as potential therapeutic targets in TNBC. Ann. Oncol. 26:67P (2015)
16.
Balluff, B.* et al.: De novo discovery of phenotypic intra-tumor heterogeneity using imaging mass spectrometry. J. Pathol. 235, 3-13 (2014)
17.
Dekker, T.J.* et al.: Multicenter Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI MSI) identifies proteomic differences in breast-cancer-associated stroma. J. Proteome Res. 13, 4730-4738 (2014)
18.
Höfig, I. et al.: Relevance of 3D-microtissues to investigate the therapeutic oncogenes HER2 and PTK6 in breast cancer. Eur. J. Cancer 50, S226 (2014)
19.
Huber, M. et al.: uPAR and its interaction partners: potential new therapy targets in triple negative breast cancer. Eur. J. Cancer 50, S161-S162 (2014)
20.
Aichler, M. et al.: Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria. J. Pathol. 230, 410-419 (2013)